Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Pharma
BMS unveils first look at late-stage Alzheimer's psychosis data
Bristol Myers Squibb is offering an early peek at its phase 3 Alzheimer's psychosis program that bodes well for the data drops ahead.
Fraiser Kansteiner
Nov 18, 2026 3:51pm
Teva's 1st R&D day lets CEO bask in innovative drug refresh
Nov 13, 2026 11:16am
Teva bags long-sought reformulated olanzapine schizophrenia nod
Oct 9, 2026 9:56am
Fierce Biotech
Teva saddles up as bidder for bankrupt BioXcel’s CNS assets
Aug 28, 2026 9:17am
Teva's innovative drugs helped carry strong Q1
Apr 29, 2026 2:27pm
Teva launches new online schizophrenia community project
Apr 15, 2026 9:45am